The use of chemical warfare agents is an ongoing, significant threat to both civilians and military personnel worldwide. Nerve agents are by far the most formidable toxicants in terms of their lethality and toxicity. Nerve agents initiate neurotoxicity by the irreversible inhibition of acetylcholinesterase and resultant accumulation of acetylcholine in excitable tissues. The cholinergic toxidrome presents as miosis, lacrimation, diarrhea, fasciculations, seizures, respiratory arrest and coma. Current medical countermeasures can attenuate acute mortality and confer limited protection against secondary neuronal injury when given rapidly after exposure. However, there is an urgent need for the development of novel, add-on neuroprotective therapies to prevent mortality and long-term toxicity of nerve agents. Increasing evidence suggests that pathways other than direct acetylcholinesterase inhibition contribute to neurotoxicity and secondary neuronal injury. Among these, oxidative stress is emerging as a key therapeutic target for nerve agent toxicity. In this review, we discuss the rationale for targeting oxidative stress in nerve agent toxicity and highlight research investigating antioxidant therapy as a neuroprotective medical countermeasure to attenuate oxidative stress, neuroinflammation and neurodegeneration.
Introduction
Preparedness against chemical warfare threats represents a critical, yet unmet need of current research efforts. To this end, in 2006 the National Institutes of Health launched the Countermeasures Against Chemical Threats (CounterACT) Program to encourage the identification of mechanisms of toxicity and the development of medical countermeasures to mitigate consequences of such exposures (Jett and Yeung, 2010) . Chemical warfare agents are highly toxic compounds, exposure to which has the potential to result in mass causalities. Exposure to such chemicals can be accidental or intentional, as was highlighted recently by the 2013 sarin gas attack on Syrian civilians (Dolgin, 2013) .
Chemical weapons vary in their mechanisms of action, target organs and lethality. Organophosphorus (OP) nerve agents such as sarin, soman, and VX are by far the most formidable in terms of their toxicity and lethal effects. In addition, OP pesticides, which share a common mechanism of action as OP nerve agents, are a significant threat from occupational, accidental and intentional exposures. The primary mechanism of toxicity in acute exposures to these compounds is the irreversible inhibition of acetylcholinesterase (AChE) in the nervous system and resultant over-activation of cholinergic tone via acetylcholine (ACh) accumulation. Depending on the degree and route of exposure, over-activation of cholinergic receptors can cause a myriad of clinical symptoms ranging from mild to severe. Perhaps the most prominent of the severe symptoms are seizures that rapidly progress to a period of unremitting seizure activity known as status epilepticus (SE). The sequelae of toxicity includes the early events of AChE inhibition and SE, delayed events such as cellular, metabolic and inflammatory changes and late outcomes i.e. neuropathology and long-term cognitive impairment. Increasing evidence suggests that other pathways play an important part in mediating the sequelae of toxicity resulting from such exposures. In this review, we discuss how early events lead to cellular oxidative stress and how targeting this phenomenon can alter delayed and functional outcomes (Fig. 1 ).
Redox imbalance
Oxidative stress occurs when the balance between oxidant production and antioxidant defenses is perturbed, resulting in the disruption of redox circuitry and macromolecular damage (Kemp et al., 2008) . Free radicals derived from molecular oxygen and nitrogen are produced as a natural by-product of aerobic metabolism and other bodily processes by both enzymatic and non-enzymatic reactions (Turrens, 2003 ). In the body, the major sources of RS are mitochondria, NADPH oxidases (NOX), haloperoxidases and the nitric oxide synthases (NOS). At low levels, RS are indispensable to host defense and signal transduction. However, increasing steady-state levels of RS results in oxidative damage to cellular lipids, proteins, sugars and DNA bases with deleterious consequences to tissue health culminating in disease (Bae et al., 2011) . Their production is therefore tightly regulated by the availability of endogenous antioxidants such as the superoxide dismutases (SOD), catalase, glutathione peroxidase (GPx), peroxiredoxins, and non-enzymatic antioxidants. Relative to other organs, the brain is relatively sparse in antioxidant defenses. This, together with the abundance of polyunsaturated lipids and high metabolic demand makes the brain particularly susceptible to RS-induced damage. Under physiologically low levels of RS, neurons are typically able to minimize RS-induced damage to cellular macromolecules through available antioxidant defenses or repair processes. Under pathological conditions when RS production is excessive and/or antioxidant and repair processes may be compromised, cellular damage causing altered cellular function can result. Specifically, damage to membrane lipids can lead to altered membrane fluidity, permeability, and structure of membrane proteins which can in turn alter neurotransmitter uptake and release in addition to the maintenance of proper ionic gradients (Wong-ekkabut et al., 2007) . Oxidative damage to cellular proteins can alter their structure and function, thereby increasing their susceptibility to proteolytic degradation and disturbing signaling pathways (Stadtman and Levine, 2000) . When produced in close enough proximity, RS can damage nuclear or mitochondrial DNA. If oxidative DNA damage exceeds what can properly be repaired by excision repair processes, the result is activation of cell death pathways (Duprez et al., 2009; Ott et al., 2007) . Neuronal cell death and inflammation are hallmark features of nerve agent toxicity and recent evidence suggests that targeting oxidative stress can attenuate these processes (Liang et al., 2018a; Liang et al., 2018b; Zaja-Milatovic et al., 2009) .
Sources of RS formation following OP nerve agent exposure
The earliest event that occurs following OP nerve agent exposure is accumulation of the toxicant in target tissues. This is followed rapidly by the inhibition of AChE and accumulation of ACh in brain and plasma. Modest evidence suggests that mere exposure to OP toxicants is sufficient to produce signs of oxidative stress (Giordano et al., 2007; Zepeda-Arce et al., 2017) . This includes studies of subacute and chronic exposures in pesticide workers where evidence of altered antioxidant status and oxidative damage is reported in the absence of AChE inhibition (Zepeda-Arce et al., 2017) . Additionally, in an in vitro model of OP toxicity, indices of oxidative stress were found even in the presence of cholinergic receptor antagonists (Giordano et al., 2007 (Akhgari et al., 2003; Kazi and Oommen, 2012; Ranjbar et al., 2002; Ranjbar et al., 2005) . Thus, as AChE inhibition increases, so does the appearance of oxidative stress.
AChE inhibition and resultant ACh receptor hyperactivation stimulates the initiation of seizures in vulnerable brain regions (McDonough and Shih, 1993; Shih and McDonough, 1997; Shih et al., 1991) . This activity is strengthened by the glutamatergic system and the resultant hyperactivation of NMDA receptors can lead to the production of RS through multiple mechanisms (Girouard et al., 2009; Gunasekar et al., 1995; Shih and McDonough, 1997) . First, activation of these receptors in hippocampal CA1 neurons for example, allows for a massive influx of extracellular calcium into the cytosol (Deshpande et al., 2010; Deshpande et al., 2014) . Increased intracellular calcium can promote the conversion of xanthine dehydrogenase to xanthine oxidase thereby initiating the excessive production of O 2 .-and H 2 O 2 (McCord, 1985) . Additionally, cytosolic calcium accumulates in mitochondria and deranges normal calcium signaling processes leading to further production of RS. Indeed, exposure to OPs has been shown to result in sustained elevations of intracellular calcium, achieved initially through NMDA receptors but maintained for up to weeks following exposure by calcium-induced calcium release from the endoplasmic reticulum (Deshpande et al., 2010; Deshpande et al., 2014) . Inhibition of this calcium plateau with dantrolene is neuroprotective in the paraxon model of OP toxicity suggesting its potential clinical relevance (Deshpande et al., 2016a; Deshpande et al., 2016b) . It is possible that this protection may be in part due to dantrolene's effect on oxidative stress (Büyükokuroğlu et al., 2008) . This suggests a potentially important relationship between initial NMDA receptor activation, elevated intracellular calcium, oxidative stress and neurodegeneration. Another consequence of activation of NMDA receptors or excessive intracellular calcium is the production of NO (Bredt, 1999; Garthwaite et al., 1989; Girouard et al., 2009) . NO reacts with O 2 .-to form the highly toxic ONOO − (Beckman and Koppenol, 1996) . Increasing evidence suggests that targeting NO production may have anti-seizure and neuroprotective effects in OP models (Gupta et al., 2001b; Kim et al., 1997; Kim et al., 1999) . Thus, activation of NMDA receptors sets into motion multiple pathways leading to the production and exacerbation of RS. Another major cause of RS formation upon exposure to toxic levels of OPs are the seizures, most commonly continuous seizures or status epilepticus (SE), they elicit. During a seizure, cerebral metabolism is increased to meet the bioenergetic demands of synchronous neuronal firing (Engel et al., 1982a, b) . Since a single episode of OP exposure is sufficient to result in chronic epilepsy, it is plausible that the underlying epileptogenic insult also shares the metabolic signatures observed in epilepsies from other etiologies (De Araujo Furtado et al., 2010; Kadar et al., 1992) . One common metabolic signature associated with human epilepsy is an increase in glucose utilization during ictal phases followed by glucose hypometabolism during the interictal phases (Chugani et al., 1994; Engel et al., 1982 Engel et al., , 1982 Gaillard et al., 1995) . Although an increase in blood flow may compensate for any bioenergetics mismatch, these energy demands can cause an imbalance in ATP production thereby depleting high energy phosphates and impairing regulated neuronal firing (Gupta et al., 2001a; Zaja-Milatovic et al., 2009) . Periods of ictal hypermetabolism followed by long periods of hypometabolism provide an ideal setting for increased steady-state levels of RS through multiple cellular sources.
Several mechanisms may contribute to increased steady-state levels of cellular O 2 .-following OP nerve agent exposure. NOX2 activation, a
, is known to increase in various models of SE (Di Maio et al., 2011; Kim et al., 2013; Patel et al., 2005; Pecorelli et al., 2015; Pestana et al., 2010 (Liang et al., 2000; Ryan et al., 2012) . Indeed, in models of chemically-induced SE and OP toxicity, O 2 .-levels are increased and contribute to neurodegeneration (Liang et al., 2000; Rieger et al., 2017) . O 2 .-serves as the precursor for much more toxic RS. H 2 O 2 , generated by spontaneous or enzymatic dismutation and peroxidases in the presence of ferrous iron via the Fenton reaction can produce the highly reactive HO% that readily oxidizes proteins, lipids, and DNA (Fenton, 1894; McCord and Day, 1978) . O 2 .-reacts with NO to produce another highly reactive product, ONOO − . Both HO% and ONOO − are potent oxidizing agents and evidence suggests that these molecules are produced as a consequence of OP-induced seizures (Jacobsson et al., 1999; Kim et al., 1997; Kim et al., 1999) . Damage to cellular macromolecules and resultant neurodegeneration induced by RS is exacerbated when antioxidant defenses are inhibited. Data from this laboratory have demonstrated that acute exposure to a convulsive dose of the model organophosphate, diisopropylfluorophosphate (DFP), or the OP nerve agent, soman is sufficient to alter the ratio of oxidized to reduced glutathione (GSH) in favor of oxidized glutathione (GSSG) (Liang et al., 2018a; Liang et al., 2018b) . These alterations to GSH/GSSG in addition to protein nitration, occur in a time-and brain region-dependent manner (Liang et al., 2018a; Liang et al., 2018b) . Oxidative stress is apparent 24 and 48 h following exposure but not at 6 or 12 h, in vulnerable brain regions such as the hippocampus and piriform cortex but not the frontal cortex (Liang et al., 2018a; Liang et al., 2018b) . In addition to serving as a specific and reliable indicator of ongoing oxidative stress in these models, the abundance of GSSG suggests a redox environment that favors oxidative stress. A common finding in most studies of OP toxicity in the brain is alterations to endogenous antioxidant systems (Brocardo et al., 2007; Brocardo et al., 2005; Giordano et al., 2007; Gupta et al., 1992; Kaur et al., 2007; Lukaszewicz-Hussain, 2008; Trevisan et al., 2008; Tüzmen et al., 2007) . Interestingly, alterations to brain antioxidant systems are not specific to acute exposures but encompass subconvulsive and chronic exposures (Lukaszewicz-Hussain, 2008; Slotkin et al., 2007; Trevisan et al., 2008; Tüzmen et al., 2007) . This suggests that seizures are not necessarily the only driving force behind OP-induced oxidative stress.
Secondary to toxicant accumulation in target tissues, receptor activation and seizures, exposure to nerve agents results in extensive neuropathology in vulnerable brain regions. Gliosis and neuronal degeneration begin to appear in a region dependent manner starting as early as 4 to 8 h following exposure (Li et al., 2011) . By 24 h after exposure, neuronal degeneration is apparent in the amygdala, hippocampus, piriform cortex and thalamus and largely co-localizes with TUNEL staining, a marker of apoptotic cell death (Li et al., 2011) . Oxidative stress and neuroinflammation, known contributors to neurodegeneration also rise dramatically during this time. In the DFP and soman models, significant oxidative damage is observed in the piriform cortex and hippocampus, two particularly vulnerable brain regions, as early as 12 to 24 h following exposure (Klaidman et al., 2003; Liang et al., 2018a; Liang et al., 2018b; Pazdernik et al., 2001) . Markers of neuroinflammation such as gliosis or increased levels of pro-inflammatory cytokines in these models typically dramatically increase at 24 h and can persist for weeks following exposure (Li et al., 2015; Li et al., 2011; Liang et al., 2018a; Liang et al., 2018b) . Pro-inflammatory cytokines and chemokines can induce RS production and conversely, excessive RS production can induce inflammation. Therefore, the persistent neuroinflammation and oxidative stress seen in these models converge in a feed forward cycle, accumulating cellular damage leading to both acute and delayed neuropathology. Given that this neuropathology occurs in brain regions imperative to normal cognitive function, damage to these areas is likely to confer functional deficits in cognition and emotionality. Indeed, survivors of nerve agent exposures often have some degree of cognitive dysfunction such as deficits in learning and memory and are more likely to have psychiatric disorders (Dolgin, 2013; Miyaki et al., 2005; Proctor et al., 2006) . Neuropathology could therefore be thought of as a surrogate to, or indicative of, functional outcomes. Evidence supporting this is beginning to emerge in the literature (Flannery et al., 2016) . Medical countermeasures that attenuate or inhibit neuropathology likely confer at least some protection against cognitive and psychiatric impairment (Pearson et al., 2015) .
Antioxidant strategies
Due to the accumulating evidence that oxidative stress plays an important part in mediating OP and nerve-agent induced toxicity, the potential to target RS pharmacologically has attracted growing interest (Table 1) . Among many available strategies, the most common is to mitigate oxidative stress in these models using small molecule antioxidant compounds with drug-like properties (Patel, 2016) . Examples of small molecule antioxidants that scavenge RS in a stoichiometric manner include α-tocopherol (vitamin E or its water-soluble form, Trolox), ascorbate (vitamin C) and thiols (e.g. N-acetyl cysteine or glutathione esters). Catalytic mechanisms can be ascribed to non-metal (e.g. nitroxides and fullernes) or metal based (e.g. metalloporphyrins and salens) compounds. Vitamin E is lipid soluble dietary antioxidant, which can access the blood brain barrier and inhibit brain lipid peroxidation. In the DFP and carbofuran rat models of OP toxicity, treatment with Vitamin E attenuated ATP depletion, oxidative damage and neurodegeneration (Gupta et al., 2001a; Gupta et al., 2001b; Jaiswal et al., 2014; Zaja-Milatovic et al., 2009) . Vitamin E interacts with lipid peroxyl radicals stochiometrically, or on a 1:1 basis, it therefore needs to be present in large amounts and in combination with ascorbate to successfully prevent membrane oxidative stress and resultant lipid damage (Matsuo et al., 1989) . Additionally, in the above mentioned studies, Vitamin E was given as a pre-treatment which is typically not feasible in the case of accidental or intentional exposure of civilians to OP nerve agents or pesticides.
Catalytic antioxidants, on the other hand, contain redox-active metal centers that catalyze the dismutation reaction of RS similar to the ability of endogenous antioxidants, allowing for regeneration of the parent compound which increases efficacy and reduces the dosage required for protection (Day, 2004 (Day et al., 1999; Kachadourian et al., 2004) . It possesses a manganese moiety which functions in the dismutation reaction with O 2 .-by alternate reduction and oxidation in a mechanism similar to endogenous SODs. Its SOD activity exceeds that of CuZnSOD when compared on a weight basis (Kachadourian et al., 2004) . In addition to the Mn center, the extensive conjugated ring system of Mn III TDE-2-ImP 5+ allows for reversible one-electron oxidations and likely confers its catalase-like activity of H 2 O 2 detoxification (Day et al., 1997) . Mn III TDE-2-ImP 5+ , in conjunction with endogenous antioxidants, acts as a ONOO − decomposition catalyst and inhibits lipid peroxidation with potent IC50s (Day et al., 1999; Lee et al., 1998 (Liang et al., 2018a; Liang et al., 2018b) . Mn III TDE-2-ImP 5+ accesses the blood brain barrier at concentrations shown to be clinically relevant in control animals and in those exposed to soman the nerve agent surrogates DFP and pilocarpine (Liang et al., 2018a; Liang et al., 2018b; Pearson et al., 2015) . In the pilocarpine rat model, when injected one hour following administration of SE and every 4 h thereafter, Mn III TDE-2-ImP 5+ significantly attenuated mortality, hippocampal oxidative stress, neurodegeneration, and learning and memory impairment (Pearson-Smith et al., 2017; Pearson et al., 2015) . Importantly, an analysis of EEG power in groups treated with vehicle or Mn III TDE-2-ImP 5+ revealed no effect of drug treatment on the intensity or duration of SE, thus suggesting that the beneficial effects of the compound can be directly attributed to its antioxidant capabilities (Pearson et al., 2015) . Similarly, in the DFP model, treatment with Mn III TDE-2-ImP 5+ did not affect brain or plasma AChE activity, suggesting that it does not act as a direct scavenger of DFP or otherwise alter AChE activity (Liang et al., 2018b) . Therefore, Mn III TDE-2-ImP 5+ not only has therapeutic potential in OP toxicity but can also serve as a tool to probe the role of oxidative stress in OP nerve agent models. Given the pharmacokinetic profile of Mn III TDE-2-ImP 5+ in surrogate and nerve agent models, comprehensive studies were performed to determine the optimal therapeutic window of the compound. In the pilocarpine model, Mn III TDE-2-ImP 5+ significantly attenuated indices of oxidative stress in both pre-exposure (30 min before pilocarpine) and post-exposure (60 or 90 min after pilocarpine) treatment paradigms (Pearson-Smith et al., 2017; Pearson et al., 2015) . Although neuropathology was not investigated in the pretreatment paradigm, treatment with Mn III TDE-2-ImP 5+ when initiated 60 min following pilocarpine significantly attenuated inflammatory cytokine production, microgliosis, mTOR activation, neurodegeneration and cognitive dysfunction (McElroy et al., 2017; Pearson et al., 2015) . When treatment with the compound was initiated 90 min after pilocarpine, microgliosis and neurodegeneration were modestly but significantly attenuated (Pearson-Smith et al., 2017) . Thus, in the pilocarpine model, the therapeutic window of Mn III TDE-2-ImP 5+ extends up to 90 min post-exposure, with optimal protection exerted when treatment with the compound is initiated 60 min after pilocarpine. In the DFP and soman rat models, treatment with Mn III TDE-2-ImP 5+ significantly attenuated indices of oxidative stress in the hippocampus and piriform cortex when given 1, 5, or 15 min after the initiation of SE (Liang et al., 2018a; Liang et al., 2018b) . Optimal protection against neuroinflammation and neurodegeneration in these models was observed when treatment with the compound began 5 min after SE initiation. SE typically develops within 10 min following exposure to DFP or soman, thus, the therapeutic window for Mn III TDE-2-ImP 5+ in these models extends up to 25 min following exposure. It is perhaps unsurprising that the therapeutic window of Mn III TDE-2-ImP 5+ shortens as the toxicity and perhaps intensity of SE induced by the toxicant increases. Of note, all rats in the above-mentioned studies received the same dose of toxicant, which would be virtually impossible in a real world scenario of chemical weapons exposure. In the case of an actual incident, people would be exposed to varying doses of the toxicant depending on a number of factors, including the proximity to the release of the toxicant. Consequently, victims would present along a spectrum of toxicity and the therapeutic window of Mn III TDE-2-ImP 5+ would vary by person. Victims exposed to the highest doses would presumably have the shortest therapeutic window while those exposed to lower doses would have the longest therapeutic windows. The utility of Mn III TDE-2-ImP 5+ extends beyond OP exposures with the ability to limit toxicity resulting from other chemical agents in postexposure treatment paradigms. Mn III TDE-2-ImP 5+ has been demonstrated to improve mortality and inhibit lung, skin and nasal damage resulting from exposure to the vesicating and alkylating agent, sulfur mustard and its analog, 2-chloroethyl ethyl sulfide (CEES) (McElroy et al., 2016; O'Neill et al., 2011; O'Neill et al., 2010; Tewari-Singh et al., 2014) . The compound was also found to protect the lung from exposure to chlorine gas (McGovern et al., 2011 Table 1 Brain studies of antioxidant therapies in OP nerve agent rat models. LPO-lipid peroxidation, PBN-phenyl-alpha-tert-butyl nitrone.
OP agent Antioxidant treatment Outcome Citation
Demeton-methyl (Metasystox)
Vitamin E Vit E prevented LPO (Tayyaba and Hasan, 1985) DFP & Carbofuran Vitamin E and PBN Vit E-partially prevented depletion of high energy phosphates PBN-prevented induced seizures and partially prevented depletion of high energy phosphates (Gupta et al., 2001a; Gupta et al., 2001b; Zaja-Milatovic et al., 2009 
Attenuated neuroinflammation, neurodegeneration (Liang et al., 2018a) J.N. Pearson-Smith and M. Patel Neurobiology of Disease xxx (xxxx) xxxx improved mortality and mitigated lung damage resulting from an acute fatal dose of radiation in non-human primates (Garofalo et al., 2014; MacVittie et al., 2017 (Zhang et al., 2018) . It may be used at the site, ambulance or in the hospital setting as it targets late effects; however, earlier intervention with daily injectable dosing would be optimal. In animals, Mn III TDE-2-ImP 5+ was effective at protecting the lung and skin when given at 5 mg/kg up to one hour after exposure to sulfur mustard or CEES (McElroy et al., 2016; O'Neill et al., 2011; O'Neill et al., 2010; Tewari-Singh et al., 2014) . Doses ranging from 5 to 7 mg/kg were sufficient to protect the brain from nerve agents and their surrogates when given 15 min to one hour following exposure (Liang et al., 2018a; Liang et al., 2018b; Pearson et al., 2015) . In mice, Mn III TDE-2-ImP 5+ was well tolerated with a no observable adverse effect level (NOAEL) of 40 mg/kg/day and a maximum tolerated dose (MTD) of 160 mg/kg/day (McGovern et al., 2011) . In human clinical studies, Mn III TDE-2-ImP 5+ was safe and well tolerated in 9 healthy subjects receiving ascending single doses (25, 50 and 75 mg), 12 patients with Amyotrophic Lateral Sclerosis (ALS) receiving multiple doses over 7 days and 28 ALS patients receiving a single dose (Zhang et al., 2018 
Limitations of antioxidant compounds in treating OP nerve agent toxicity
Although we provide a strong rationale for antioxidant therapies in OP nerve agent toxicity, several barriers to effective treatment must also be considered. First, any potential therapeutic compound must possess rapid entry and maintain sufficient concentrations in the brain to counteract the CNS effects of nerve agent exposure. While Mn III TDE- (Kelso et al., 2001 (Liang et al., 2018a; Liang et al., 2018b 
Concluding remarks
There are multiple shared mechanisms by which redox imbalance and oxidative stress occurs following exposure to chemical warfare agents. In models of OP toxicity, oxidative stress regardless of its source, can lead to secondary neuronal injury. Antioxidant treatment strategies therefore, represent a novel and promising approach to target secondary neuronal injury and exert neuroprotection.
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